Immupharma Regulatory News (IMM)

FOR IMMEDIATE RELEASE 29 FEBRUARY 2012

ImmuPharma plc

Appoints Head of Investor Relations

ImmuPharma plc (AIM: IMM), the specialist drug development company, is pleased to announce that it has appointed Lisa Baderoon as Head of Investor Relations.

Lisa Baderoon has spent over 20 years working within the City, the majority of that time as a Partner of Buchanan, one of the leading City financial public relations agencies, where she helped establish its successful healthcare franchise.

Commenting on her appointment Lisa Baderoon said:"At Buchanan I advised ImmuPharma for over six years so I am extremely excited that I now have the opportunity of working even more closely with the management team on its IR strategy at one of the most exciting and pivotal stages in its development."

Dimitri Dimitriou, Chief Executive Officer of ImmuPharma, added:"Lisa brings a wealth of experience to ImmuPharma having advised not only us but many other companies within the healthcare sector. We are therefore delighted that she is now going to be part of our team."

- Ends -

For further information please contact:

ImmuPharma plc

Dimitri Dimitriou, Chief Executive Officer Tel No: + 44 (0) 20 7152 4080

Lisa Baderoon, Head of Investor Relations Tel No: + 44 (0) 7721 413496

Buchanan  Tel No: + 44 (0) 20 7466 5000

Mark Court, Jessica Fontaine